

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)


PCT

(10) International Publication Number  
**WO 03/061639 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/00**
- (21) International Application Number: **PCT/CA03/00079**
- (22) International Filing Date: 27 January 2003 (27.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/350,955 25 January 2002 (25.01.2002) US
- (71) Applicant (for all designated States except US): **DI-AMEDICA INC.** [CA/CA]; 6-1200 Waverley Street, Winnipeg, Manitoba R3T 0P4 (CA).
- (71) Applicants and  
(72) Inventors: **LAUTT, W., Wayne** [CA/CA]; 631 Drake Centre, 181 Freedman Crescent, Winnipeg, Manitoba R3T 5V4 (CA). **MACEDO, Paula** [PT/PT]; Caminho do Forte 1, 2780 Caxias, Oeiras (PT).
- (74) Agent: **MCKAY, Margaret, H.**; Ridout & Maybee LLP, 150 Metcalfe Street, Suite 1900, Ottawa, Ontario K2P 1P1 (CA).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: **USE OF GLUTATHIONE SYNTHESIS STIMULATING COMPOUNDS IN REDUCING INSULIN RESISTANCE**



(57) Abstract: There is provided a method of reducing insulin resistance in a mammalian patient comprising selecting a patient suffering from insulin resistance and administering a compound which increases hepatic glutathione and a compound which increases hepatic nitric oxide.

WO 03/061639 A2